Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement

Richard Schwab, Istvan Petak, Mihaly Kollar, Ferenc Pinter, Edit Varkondi, Andrea Kohanka, Helga Barti-Juhasz, Julia Schönleber, Diana Brauswetter, Laszlo Kopper, Laszlo Urban

Research output: Contribution to journalArticle

43 Citations (Scopus)


The initial radiotherapy of a 73 years old Caucasian male patient with advanced squamous cell lung carcinoma was terminated due to severe pericarditis. Subsequently, the tumor sample was analyzed for possible targets with comprehensive molecular diagnostics. EGFR, KRAS and PIK3CA genes were wild type, ALK and ROS1 were negative for rearrangement, but c-MET was amplified by fluorescent in situ hybridization. The kinase inhibitor crizotinib is already in clinical use for the treatment of ALK positive non-small cell lung cancers, but it is also known to be a potent c-MET inhibitor. The patient was treated with the standard dose of twice a day 250. mg crizotinib as a monotherapy. Major partial response to therapy was confirmed by chest CT and PET/CT after 8 weeks on therapy. C-MET expression is associated with poor prognosis and resistance to EGFR inhibitors. This case may indicate that c-MET tyrosine kinase inhibitors can be an effective targeted treatment option for squamous cell carcinoma patients, and future clinical trials should be expanded for this patient group as well.

Original languageEnglish
Pages (from-to)109-111
Number of pages3
JournalLung Cancer
Issue number1
Publication statusPublished - Jan 1 2014



  • C-MET
  • Crizotinib
  • Non-small cell lung cancer
  • Personalized medicine
  • Pharmacogenomics
  • Predictive biomarker
  • Receptor tyrosine kinase
  • Squamous cell lung cancer
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this